Nyxoah SA (NASDAQ:NYXH – Get Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 826,117 shares, an increase of 185.5% from the May 31st total of 289,376 shares. Currently, 2.6% of the shares of the company are sold short. Based on an average daily volume of 965,701 shares, the days-to-cover ratio is presently 0.9 days.
Hedge Funds Weigh In On Nyxoah
Several institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in Nyxoah by 72.4% in the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after buying an additional 3,303 shares in the last quarter. Raymond James Financial Inc. increased its holdings in shares of Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after buying an additional 3,353 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after buying an additional 10,000 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Nyxoah in the third quarter valued at approximately $98,000. Finally, Shay Capital LLC bought a new position in shares of Nyxoah in the second quarter valued at approximately $374,000.
Nyxoah Price Performance
NYXH stock traded up $0.04 during trading on Friday, hitting $1.67. The company had a trading volume of 112,734 shares, compared to its average volume of 705,644. The company has a fifty day moving average price of $2.54 and a two-hundred day moving average price of $3.63. The company has a current ratio of 0.99, a quick ratio of 0.88 and a debt-to-equity ratio of 0.53. The company has a market cap of $64.73 million, a P/E ratio of -0.67 and a beta of 1.55. Nyxoah has a fifty-two week low of $1.26 and a fifty-two week high of $8.59.
Wall Street Analyst Weigh In
Several brokerages have issued reports on NYXH. Stifel Nicolaus lowered their price target on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, June 17th. Piper Sandler reaffirmed an “overweight” rating and set a $7.00 price objective (down from $9.00) on shares of Nyxoah in a report on Wednesday, May 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 target price on shares of Nyxoah in a research report on Monday, March 23rd. Finally, Weiss Ratings cut shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.00.
Read Our Latest Stock Report on Nyxoah
About Nyxoah
Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.
The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.
Featured Articles
- Five stocks we like better than Nyxoah
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
